Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 19-Apr-21 7:57 PM View:  | Smith David V Executive Vice President & CFO | Five Prime Therapeutics, Inc. (FPRX) | 16-Apr-21 | Grant | 66,000 | -- | -- | 90% 72.95K to 138.95K | |
| 19-Apr-21 8:04 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 16-Apr-21 | Disposition | 2,385 | $38.00 | $90,630.00 | (100%) 2.38K to 0 | |
| 19-Apr-21 7:49 PM View: | White David See Remarks | Five Prime Therapeutics, Inc. (FPRX) | 16-Apr-21 | Disposition | 33,423 | $38.00 | $1,270,070.00 | (100%) 33.42K to 0 | 0% |
| 19-Apr-21 7:57 PM View: | Smith David V Executive Vice President & CFO | Five Prime Therapeutics, Inc. (FPRX) | 16-Apr-21 | Disposition | 138,947 | $38.00 | $5,279,990.00 | (100%) 138.95K to 0 | |
| 19-Apr-21 8:04 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 16-Apr-21 | Grant | 66,000 | -- | -- | 62% 105.85K to 171.85K | |
| 19-Apr-21 7:53 PM View: | Collins Helen Louise EVP and Chief Medical Officer | Five Prime Therapeutics, Inc. (FPRX) | 16-Apr-21 | Grant | 66,000 | -- | -- | 95% 69.55K to 135.55K | |
| 19-Apr-21 7:21 PM View: | Civik Thomas President and CEO Director | Five Prime Therapeutics, Inc. (FPRX) | 16-Apr-21 | Disposition | 68,971 | $38.00 | $2,620,900.00 | (100%) 68.97K to 0 | 0% |
| 19-Apr-21 7:42 PM View: | Berger Franklin M Director | Five Prime Therapeutics, Inc. (FPRX) | 16-Apr-21 | Disposition | 5,000 | $38.00 | $190,000.00 | (100%) 5.0K to 0 | 0% |
| 19-Apr-21 8:04 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 16-Apr-21 | Disposition | 169,468 | $38.00 | $6,439,780.00 | (99%) 171.85K to 2.38K | |
| 19-Apr-21 7:53 PM View: | Collins Helen Louise EVP and Chief Medical Officer | Five Prime Therapeutics, Inc. (FPRX) | 16-Apr-21 | Disposition | 135,547 | $38.00 | $5,150,790.00 | (100%) 135.55K to 0 | |
| 13-Apr-21 1:05 PM View: | Civik Thomas President and CEO Director | Five Prime Therapeutics, Inc. (FPRX) | 09-Apr-21 | Payment of Exercise | 11,088 | $37.94 | $420,679.00 | (14%) 80.06K to 68.97K | (< 1%) |
| 19-Apr-21 8:04 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 06-Apr-21 | Gift | 14,174 | -- | -- | (12%) 119.23K to 105.06K | |
| 19-Apr-21 7:46 PM View: | Ringo William R Director | Five Prime Therapeutics, Inc. (FPRX) | 05-Apr-21 | Gift | 10,000 | -- | -- | (100%) 10.0K to 0 | |
| 19-Apr-21 8:04 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 05-Apr-21 | Gift | 2,460 | -- | -- | (2%) 121.69K to 119.23K | |
| 19-Apr-21 8:04 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 01-Apr-21 | Gift | 3,825 | -- | -- | (3%) 125.52K to 121.69K | |
| 19-Apr-21 8:04 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 01-Apr-21 | Gift | 2,385 | -- | -- | 2% 123.13K to 125.52K | |
| 19-Apr-21 7:53 PM View: | Collins Helen Louise EVP and Chief Medical Officer | Five Prime Therapeutics, Inc. (FPRX) | 31-Mar-21 | Gift | 8,085 | -- | -- | (10%) 77.63K to 69.55K | |
| 02-Mar-21 12:00 PM View: | White David See Remarks | Five Prime Therapeutics, Inc. (FPRX) | 28-Feb-21 | Payment of Exercise | 1,461 | $22.23 | $32,478.00 | (4%) 34.88K to 33.42K | (71%) |
| 02-Mar-21 12:16 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 26-Feb-21 | Payment of Exercise | 1,158 | $22.23 | $25,742.30 | (< 1%) 124.59K to 123.43K | (71%) |
| 02-Mar-21 12:08 PM View: | Collins Helen Louise EVP and Chief Medical Officer | Five Prime Therapeutics, Inc. (FPRX) | 26-Feb-21 | Payment of Exercise | 1,158 | $22.23 | $25,742.30 | (1%) 78.79K to 77.63K | (71%) |
| 26-Feb-21 2:42 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 25-Feb-21 | Payment of Exercise | 1,653 | $23.08 | $38,151.20 | (1%) 126.24K to 124.59K | (65%) |
| 26-Feb-21 2:36 PM View: | Collins Helen Louise EVP and Chief Medical Officer | Five Prime Therapeutics, Inc. (FPRX) | 25-Feb-21 | Payment of Exercise | 1,653 | $23.08 | $38,151.20 | (2%) 80.44K to 78.79K | (65%) |
| 26-Feb-21 2:36 PM View: | Collins Helen Louise EVP and Chief Medical Officer | Five Prime Therapeutics, Inc. (FPRX) | 24-Feb-21 | Payment of Exercise | 5,091 | $25.71 | $130,890.00 | (6%) 85.53K to 80.44K | (48%) |
| 26-Feb-21 2:31 PM View: | Smith David V Executive Vice President & CFO | Five Prime Therapeutics, Inc. (FPRX) | 24-Feb-21 | Payment of Exercise | 5,110 | $25.71 | $131,378.00 | (7%) 78.06K to 72.95K | (48%) |
| 26-Feb-21 2:26 PM View: | White David See Remarks | Five Prime Therapeutics, Inc. (FPRX) | 24-Feb-21 | Payment of Exercise | 1,155 | $25.71 | $29,695.00 | (3%) 36.04K to 34.88K | (48%) |
| 26-Feb-21 2:42 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 24-Feb-21 | Payment of Exercise | 5,100 | $25.71 | $131,121.00 | (4%) 131.34K to 126.24K | (48%) |
| 15-Dec-20 12:19 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 11-Dec-20 | Option Exercise | 22,000 | -- | -- | 19% 116.01K to 138.01K | |
| 15-Dec-20 12:19 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 11-Dec-20 | Payment of Exercise | 11,583 | $16.14 | $186,950.00 | (8%) 138.01K to 126.43K | (135%) |
| 15-Dec-20 12:00 PM View: | Collins Helen Louise EVP and Chief Medical Officer | Five Prime Therapeutics, Inc. (FPRX) | 11-Dec-20 | Payment of Exercise | 11,583 | $16.14 | $186,950.00 | (12%) 97.12K to 85.53K | (135%) |
| 15-Dec-20 12:09 PM View: | Smith David V Executive Vice President & CFO | Five Prime Therapeutics, Inc. (FPRX) | 11-Dec-20 | Payment of Exercise | 11,504 | $16.14 | $185,675.00 | (13%) 89.56K to 78.06K | (135%) |
| 15-Dec-20 12:00 PM View: | Collins Helen Louise EVP and Chief Medical Officer | Five Prime Therapeutics, Inc. (FPRX) | 11-Dec-20 | Option Exercise | 22,000 | -- | -- | 29% 75.12K to 97.12K | |
| 15-Dec-20 12:09 PM View: | Smith David V Executive Vice President & CFO | Five Prime Therapeutics, Inc. (FPRX) | 11-Dec-20 | Option Exercise | 22,000 | -- | -- | 33% 67.56K to 89.56K | |
| 30-Nov-20 2:49 PM View: | Smith David V Executive Vice President & CFO | Five Prime Therapeutics, Inc. (FPRX) | 26-Nov-20 | Payment of Exercise | 6,920 | $18.45 | $127,674.00 | (9%) 74.48K to 67.56K | (106%) |
| 13-Nov-20 12:17 PM View: | Ringo William R Director | Five Prime Therapeutics, Inc. (FPRX) | 11-Nov-20 | Market Option Sale (Planned) | 78,959 | $22.50 | $1,776,580.00 | (89%) 88.96K to 10.0K | (69%) |
| 13-Nov-20 12:29 PM View: | Smith David V Executive Vice President & CFO | Five Prime Therapeutics, Inc. (FPRX) | 11-Nov-20 | Payment of Exercise | 10,908 | $18.00 | $196,344.00 | (13%) 85.39K to 74.48K | (111%) |
| 13-Nov-20 12:38 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 11-Nov-20 | Payment of Exercise | 11,001 | $18.00 | $198,018.00 | (9%) 127.01K to 116.01K | (111%) |
| 13-Nov-20 12:25 PM View: | Collins Helen Louise EVP and Chief Medical Officer | Five Prime Therapeutics, Inc. (FPRX) | 11-Nov-20 | Payment of Exercise | 11,039 | $18.00 | $198,702.00 | (13%) 86.16K to 75.12K | (111%) |
| 13-Nov-20 5:29 PM View: | Bvf Partners L P/il | Five Prime Therapeutics, Inc. (FPRX) | 11-Nov-20 | Market Sale | 7,393,340 | $20.19 | $149,247,008.00 | (86%) 8.63M to 1.24M | (88%) |
| 13-Nov-20 12:25 PM View: | Collins Helen Louise EVP and Chief Medical Officer | Five Prime Therapeutics, Inc. (FPRX) | 11-Nov-20 | Option Exercise | 22,000 | -- | -- | 34% 64.16K to 86.16K | |
| 13-Nov-20 12:29 PM View: | Smith David V Executive Vice President & CFO | Five Prime Therapeutics, Inc. (FPRX) | 11-Nov-20 | Option Exercise | 22,000 | -- | -- | 35% 63.39K to 85.39K | |
| 13-Nov-20 12:17 PM View: | Ringo William R Director | Five Prime Therapeutics, Inc. (FPRX) | 11-Nov-20 | Option Exercise | 78,959 | $2.41 | $190,369.00 | 790% 10.0K to 88.96K | |
| 13-Nov-20 12:38 PM View: | Sarena Francis Willard Chief Strategy Officer | Five Prime Therapeutics, Inc. (FPRX) | 11-Nov-20 | Option Exercise | 22,000 | -- | -- | 21% 105.01K to 127.01K | |
| 06-Nov-20 6:30 PM View: | Bvf Partners L P/il 10% Owner | Five Prime Therapeutics, Inc. (FPRX) | 06-Nov-20 | Market Purchase | 30,000 | $4.98 | $149,520.00 | < 1% 8.6M to 8.63M | 662% |
| 06-Nov-20 6:30 PM View: | Bvf Partners L P/il 10% Owner | Five Prime Therapeutics, Inc. (FPRX) | 04-Nov-20 | Market Purchase | 416,562 | $4.88 | $2,034,570.00 | 5% 8.18M to 8.6M | 678% |
| 08-Oct-20 5:27 PM View: | Bvf Partners L P/il 10% Owner | Five Prime Therapeutics, Inc. (FPRX) | 06-Oct-20 | Market Purchase | 345,241 | $5.03 | $1,738,290.00 | 4% 7.84M to 8.18M | 655% |
| 02-Oct-20 1:51 PM View: | White David See Remarks | Five Prime Therapeutics, Inc. (FPRX) | 30-Sep-20 | Payment of Exercise | 6,916 | $4.70 | $32,505.20 | (16%) 42.95K to 36.04K | (708%) |
| 24-Sep-20 7:49 PM View: | Bvf Partners L P/il 10% Owner | Five Prime Therapeutics, Inc. (FPRX) | 22-Sep-20 | Market Purchase | 32 | $3.80 | $121.56 | < 1% 7.84M to 7.84M | 900% |
| 24-Aug-20 1:46 PM View: | Collins Helen Louise EVP and Chief Medical Officer | Five Prime Therapeutics, Inc. (FPRX) | 20-Aug-20 | Payment of Exercise | 827 | $4.69 | $3,878.63 | (1%) 64.98K to 64.16K | (709%) |
| 18-May-20 8:02 PM View: | Bvf Partners L P/il 10% Owner | Five Prime Therapeutics, Inc. (FPRX) | 14-May-20 | Market Purchase | 293,587 | $4.10 | $1,203,710.00 | 4% 7.55M to 7.84M | 825% |
| 14-Apr-20 4:38 PM View: | Civik Thomas President and CEO Director | Five Prime Therapeutics, Inc. (FPRX) | 13-Apr-20 | Grant | 75,000 | -- | -- | 100% 0 to 75.0K |
